Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1627223/000156459021054925/cc-10q_20210930.htm
May 2022
April 2022
March 2022
February 2022
February 2022
December 2021
December 2021
November 2021
October 2021
October 2021
EXHIBIT 99.1
The Chemours Company Reports Strong Third Quarter Results and
Increases Full-Year 2021 Outlook
Market strength and operational excellence drove strong quarterly performance, raising outlook as confidence builds
Wilmington, Del., November 4, 2021 -- The Chemours Company (“Chemours”) (NYSE: CC), a global chemistry company with leading market positions in Titanium Technologies, Thermal & Specialized Solutions, Advanced Performance Materials, and Chemical Solutions today announces its financial results for the third quarter 2021.
Third Quarter 2021 Results & Highlights
|
• |
Net Sales of $1.7 billion, up 36% year-over-year |
|
• |
Net Income of $214 million with EPS of $1.27, up $0.81 year-over-year |
|
• |
Adjusted Net Income* of $214 million with Adjusted EPS* of $1.27, up $0.80 year-over-year |
|
• |
Adjusted EBITDA* of $372 million, up 77% year-over-year, resulting in Free Cash Flow of $244 million |
|
• |
Repurchased $67 million of common stock during the quarter, repaid $108 million of debt principal, and funded $100 million escrow payment as per the MOU agreement |
|
• |
U.S. EPA established final rules for the phasedown of HFC refrigerants under the U.S. AIM Act designed to accelerate widespread use of climate friendly and energy efficient alternatives such as our low global warming potential Opteon™ solutions |
|
• |
On October 27, 2021, the company's Board of Directors approved a fourth quarter dividend of $0.25 per share, consistent with the prior quarter |
2021 Revised Outlook
|
• |
Adjusted EBITDA* between $1,300 million and $1,340 million, vs. prior guidance in the top-end of $1,100 million to $1,250 million range |
|
• |
Adjusted EPS* between ~$3.93 and $4.13 vs. prior guidance in the top-end of ~$2.84 to $3.56 range |
|
• |
Free Cash Flow* now expected to be greater than $500 million vs. prior outlook of greater than $450 million. Capex guidance lowered to ~$325 million from ~$350 million previously, mainly driven by timing of projects |
“The Chemours team continues to demonstrate resilience along with a renewed focus on sustainable growth of our key businesses. We have met every challenge head on, continue to prioritize and serve our customers, and uphold our commitments to all stakeholders despite the difficult operating environment,” said Chemours President and CEO Mark Newman. “Our strong top line, bottom line and cash results in the quarter demonstrate the strength of this business and the progress we are making towards better quality of earnings and higher shareholder returns. I am confident that we have the right business strategies, an inspired group of leaders and empowered employees to consistently deliver across cycles and over time.”
Third quarter 2021 Net Sales were $1.7 billion, 36% higher than the prior-year quarter. 25% volume growth was the primary driver of the better year-over-year sales performance with positive contributions from every segment. 11% higher pricing and 1% favorable currency translation more than offset a 1% portfolio impact stemming from the exit of our Aniline business in the fourth quarter 2020. The 2% sequential sales improvement was driven primarily by strengthening pricing trends across the portfolio. Volume declined 2% quarter-over-quarter as strong market demand in most product categories was offset by certain customer production constraints, raw material availability, and typical seasonal factors across different parts of the portfolio.
Third quarter Net Income was $214 million, or $1.27 of EPS. Adjusted Net Income was $214 million. Adjusted EPS was $1.27, up $0.80 vs. the prior-year quarter. Adjusted EBITDA for the third quarter 2021 was $372 million in comparison to $210 million in the prior-year third quarter, a result of higher volume, pricing and a favorable currency impact, partially offset by incremental cost headwinds associated with higher plant fixed costs to increase production to meet higher demand, raw material inflation, and higher performance-related compensation expense.
* For information on our non-GAAP measures, please refer to the attached “Reconciliation of GAAP Financial Measures to non-GAAP Financial Measures (Unaudited)”
Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1627223/000156459021054925/cc-10q_20210930.htm
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Chemours Co.
Chemours Co's Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:
Rating
Learn More![]()
Our financial policy seeks to: (i) selectively invest in organic and inorganic growth to enhance our portfolio, including certain strategic capital investments; (ii) maintain appropriate leverage by using free cash flows to repay outstanding borrowings; and, (iii) return cash to shareholders through dividends and share repurchases.
Adjusted EBITDA and Adjusted EBITDA Margin For the three months ended September 30, 2021, segment Adjusted EBITDA increased by $64 million (or over 100%) to $71 million and Adjusted EBITDA margin increased by approximately 1,700 basis points to 20%, compared with segment Adjusted EBITDA of $7 million and Adjusted EBITDA margin of 3% for the same period in 2020.
Adjusted EBITDA and Adjusted EBITDA Margin For the three months ended September 30, 2021, segment Adjusted EBITDA increased by $94 million (or 73%) to $223 million and Adjusted EBITDA margin increased by approximately 400 basis points to 25%, compared with segment Adjusted EBITDA of $129 million and Adjusted EBITDA margin of 21% for the same period in 2020.
Adjusted EBITDA and Adjusted EBITDA Margin For the three months ended September 30, 2021, segment Adjusted EBITDA increased by $3 million (or 25%) to $15 million and Adjusted EBITDA margin increased by approximately 100 basis points to 15%, compared with segment Adjusted EBITDA of $12 million and Adjusted EBITDA margin of 14% for the same period in 2020.
The increases in our SG&A...Read more
Unanticipated schedule delays or other...Read more
The components of the increase...Read more
To supplement our financial information...Read more
For the nine months ended...Read more
For the nine months ended...Read more
For the nine months ended...Read more
The increase in our operating...Read more
The increases in our COGS...Read more
The increase in segment Adjusted...Read more
The increases in our research...Read more
Factors that could cause or...Read more
The $43 million increase in...Read more
The components of the increase...Read more
The increase in Corporate and...Read more
However, the required TSCA order...Read more
61 Adjusted EBITDA and Adjusted...Read more
84 The following table sets...Read more
Our presentation of Adjusted EBITDA,...Read more
The increases in segment Adjusted...Read more
62 The following table sets...Read more
60 The following table sets...Read more
63 The following table sets...Read more
59 The following table sets...Read more
The $33 million increase in...Read more
(Dollars in millions) Net sales...Read more
Additionally, our Corporate Responsibility Commitment...Read more
The increase in our inventories...Read more
Furthermore, the recent change in...Read more
Within the later of (i)...Read more
As final clean-up activities for...Read more
The decrease in our interest...Read more
Our other accrued liabilities decreased...Read more
Our equity in earnings of...Read more
The following table sets forth...Read more
Our estimated liability for the...Read more
73 Consistent with our values...Read more
We believe the presentation of...Read more
Our interest expense, net decreased...Read more
We have not accrued for...Read more
77 The volume of groundwater,...Read more
Volume increases were driven by...Read more
Volume increases were driven by...Read more
Remaining work beyond continued operation...Read more
This was offset substantially by...Read more
We utilize Adjusted EBITDA as...Read more
Our cost of goods sold...Read more
These goals are designed to...Read more
We call this responsible chemistry...Read more
Favorable currency movements also added...Read more
Favorable currency movements also added...Read more
Favorable currency movements added a...Read more
Favorable currency movements added a...Read more
Favorable currency movements added a...Read more
Favorable currency movements added a...Read more
Favorable currency movements added a...Read more
Favorable currency movements added a...Read more
The increase in our accounts...Read more
For the nine months ended...Read more
The non-GAAP financial measures we...Read more
With this focus, we continue...Read more
After a period of public...Read more
The following table sets forth...Read more
Our financing cash outflows for...Read more
(7) Includes the removal of...Read more
The decrease in our other...Read more
In large part, because of...Read more
Our inventories increased by $77...Read more
In addition, portfolio changes, such...Read more
The decrease in our other...Read more
The increase in our compensation...Read more
Our obligations to our suppliers,...Read more
Such charges could have a...Read more
Our Advanced Performance Materials segment's...Read more
As more sites advance from...Read more
Volumes increased due to higher...Read more
Volumes increased due to higher...Read more
Volumes increased primarily due to...Read more
Volumes increased due to increased...Read more
The increase in our prepaid...Read more
For the nine months ended...Read more
Our Titanium Technologies segment's net...Read more
Our Thermal & Specialized Solutions...Read more
Segment Net Sales Our Chemical...Read more
Our Chemical Solutions segment's net...Read more
Our net sales increased by...Read more
55 Our net sales increased...Read more
Where necessary, based on COVID-19...Read more
This increase in our accounts...Read more
(4) Qualified spend recovery represents...Read more
It is also possible that,...Read more
The increase in our accounts...Read more
In accordance with ASC 410...Read more
While the Non-Guarantor Subsidiaries do...Read more
A reconciliation of net income...Read more
Accordingly, we have increased the...Read more
Volumes increased due to higher...Read more
Volumes increased due to higher...Read more
In the third quarter of...Read more
Consistent with our Corporate Responsibility...Read more
Adjusted earnings before interest, taxes,...Read more
The lawsuit requested a declaratory...Read more
As an energy and emissions...Read more
Therefore, considerable uncertainty exists with...Read more
Our global workforce, renowned for...Read more
The net proceeds from the...Read more
The net proceeds from the...Read more
An incremental $60 million was...Read more
Our selling, general, and administrative...Read more
(1) The nine months ended...Read more
The division into three zones...Read more
The increase in our equity...Read more
(5) Legal charges pertains to...Read more
The approximate 440-acre site is...Read more
We also expect to recognize...Read more
More recently, in March 2017,...Read more
Our ability to meet our...Read more
The risks and uncertainties posed...Read more
Average prices increased primarily due...Read more
We expect that our future...Read more
These agreements primarily pertain to...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Material Contracts, Statements, Certifications & more
Chemours Co provided additional information to their SEC Filing as exhibits
Ticker: CC
CIK: 1627223
Form Type: 10-Q Quarterly Report
Accession Number: 0001564590-21-054925
Submitted to the SEC: Fri Nov 05 2021 4:51:59 PM EST
Accepted by the SEC: Fri Nov 05 2021
Period: Thursday, September 30, 2021
Industry: Chemicals And Allied Products